The covid vaccine maker BioNTech said on Monday it would build a headquarter in Southeast Asia and open a new headquarter in Singapore. The German biotechnology company will produce hundreds of millions of mRNA-based vaccines per year.
The new construction headquarter will start this year, and it could become functional by 2023, the company said in a statement. It would allow the companies to scale up production in Southeast Asia by addressing future pandemic threats.
BioNTech jointly with Pfizer of the United States is using mRNA technology which makes use of genetic material to provoke an immune response against the virus.
It is now supplying vaccines to more than 90 countries worldwide and is planning to increase its production by 3 billion doses by the end of the year. This pace will further accelerate in 2022.
The Singapore production site will be the BioNTech’s first mRNA manufacturing facility outside Europe, and will have an expected capacity of several hundred million doses of such vaccines.
“With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world,” said BioNTech CEO and co-founder – Ugur Sahin.
“Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities,” Sahin added.